Evangelos Konstantinidis, Agnieszka Molisak, Florian Perrin, Linn Streubel-Gallasch, Sarah Fayad, Daniel Y. Kim, . . . Martin Ingelsson. (2022). CRISPR-Cas9 treatment partially restores amyloid-β 42/40 in human fibroblasts with the Alzheimer's disease PSEN1 M146L mutation. Elsevier.
Chicago-referens (17:e uppl.)Evangelos Konstantinidis, et al. CRISPR-Cas9 Treatment Partially Restores Amyloid-β 42/40 in Human Fibroblasts with the Alzheimer's Disease PSEN1 M146L Mutation. Elsevier, 2022.
MLA-referens (9:e uppl.)Evangelos Konstantinidis, et al. CRISPR-Cas9 Treatment Partially Restores Amyloid-β 42/40 in Human Fibroblasts with the Alzheimer's Disease PSEN1 M146L Mutation. Elsevier, 2022.
Varning: dessa hänvisningar är inte alltid fullständigt riktiga.